Atlanta, Georgia, United States The main department of described Corporate Investor is located in the Atlanta. The company was established in North America in United States.
The standard case for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Sabby Management, Redmile Group, Deerfield. In the next rounds fund is usually obtained by Wild Basin Investments, Merieux Developpement, Silicon Valley Bank.
Among the most successful fund investment fields, there are Health Care, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Xeris Pharmaceuticals. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund.
The higher amount of exits for fund were in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2016. The fund is constantly included in less than 2 investment rounds annually.
| Fund Name | Location |
| Altitude Ventures | Nashville, Tennessee, United States |
| Barrow Cadbury Trust | England, London, United Kingdom |
| Cascabel Management | New York, New York, United States |
| Cyberport Macro Fund (CMF) | - |
| Dai-ichi Seiko | Japan, Kyoto, Kyoto Prefecture |
| Endicott Group | New York, New York, United States |
| Haitong Anyuan | China, Shaanxi, Xian Shi |
| Lengshan Touzi | Beijing, China, Haidian |
| Nan Fung | China, Hong Kong, Hong Kong Island |
| Nine Four Ventures | Chicago, Illinois, United States |
| Prelude | Salt Lake City, United States, Utah |
| SC Ventures | New York, New York, United States |
| Steadfast Capital | Frankfurt, Germany, Hessen |
| Tasseo Consumer Ecosystem | - |
| The Spruce House Partnership | New York, New York, United States |
| Timon Capital | Lagos, Lagos, Nigeria |
| Z Ventures Group | China, Shanghai |
| Zhongluan Investment | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Xeris Pharmaceuticals | $41M | 07 Jan 2016 | Chicago, Illinois, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Xeris Pharmaceuticals | $41M | 07 Jan 2016 | Chicago, Illinois, United States |
